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Abstract
HEPES (4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid) is a buffer that is used in
the radiolabelling of gallium-68 compounds. The beneficial effects of HEPES on
molar activity in bioconjugates have been well described. Current strict regulations
on the HEPES content in radiopharmaceuticals limit its use when intended for
parenteral administration.
This short communication summarizes data from the literature on the toxicity of
HEPES in dogs after intravenous infusion and the subsequent use in humans. We
also highlight the use of HEPES in an FDA labelled intravenous drug formulation.
Regulatory institutions may consider this data to review current strict limits.
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Use of HEPES in pharmaceutical products
Radiosynthesis of gallium-68 compounds often requires a labelling mixture with a pH of
3.5–5.0 to ensure good complexation of gallium-68 with the precursor. Buffers such as 4-
(2-hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES) and sodium acetate are ex-
tensively used in the labelling of radiopharmaceuticals with gallium-68. These buffers are
reported to have low metallic complexation properties making them suitable to adjust
pH during labelling and reduce formation of colloids (Bauwens et al. 2010).
HEPES, a zwitterionic buffer, is listed as a Good’s buffer with a pKa of 3.0 and 7.55
(Good et al. 1966). Velikyan et al. illustrated the beneficial effect of HEPES on specific
activity in radiolabelling bioconjugates (Velikyan et al. 2004). A number of references
indicate that adjusting the pH with HEPES during radiolabelling with gallium-68 pro-
vides optimum results in terms of molecular activity, reproducibility, reliability and
versatility (Bauwens et al. 2010; Eppard et al. 2014; Pfaff et al. 2018; Velikyan et al.
2004). The European Pharmacopoeia prescribes a strict limit of 200 μg per dose for the
HEPES content in radiopharmaceuticals intended for intravenous administration
(European Pharmacopeia 2017). However, the method described in the European
Pharmacopoeia to test for HEPES in radiopharmaceutical preparations has proven to
be unreliable (Antunes et al. 2020; Pfaff et al. 2018; Sasson et al. 2010). The low limit
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has hampered the use of HEPES in gallium-68 radiopharmaceuticals, despite its super-
ior buffering properties. A lack of toxicological data, especially after intravenous admin-
istration is generally cited as the main reason for these strict limits (Bauwens et al.
2010; European Pharmacopeia 2017; Sasson et al. 2010).
A chronic tolerance study of 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid
(product code TVZ-7), published in 1997 by Theodore et al., provides important data
on HEPES toxicity in beagle dogs after intravenous infusion (Theodore et al. 1997a).
The animals were monitored for pharmacological or toxicological effects from increas-
ing HEPES doses of 5–500 mg/kg, administered over a period of 148 days. Initially
doses were administered daily via intravenous infusion but then changed to alternate
days because of a subjective observation of stress at doses reaching 300, 350 and 400
mg/kg. Routine clinical pathology evaluations consisted of complete blood count and
blood chemistry. Histopathology (bone marrow and liver biopsies) was done at the end
of the highest dose segment when clinical effects were observed. Important results from
the study included the following:
a) Vomiting, a pharmacological effect of HEPES administration, occurred in the first
two segments of the study but subsided when HEPES was administered before
feeds.
b) When I.V. doses approached 400 mg/kg (4000 mg for a dog with an average weight
of 10 kg), significant changes in hematopoietic and reticuloendothelial system were
observed in some dogs. These included hypercellular bone marrow and
extramedullary hematopoiesis.
The study however concluded that no serious adverse effects are associated with
chronic intravenous administration of HEPES in doses ranging from 5 to 500 mg/kg. In
a patient with an average weight of 70 kg, this would amount to a maximum dose of
35,000 mg (35 g).
A more significant publication is the preliminary evaluation of a fixed dose of HEPES
in humans by Theodore et al. The investigators report on the use of HEPES to evaluate
its potential beneficial effects in clinical cancer (Theodore et al. 1997b). In this study,
most subjects received an average fixed daily dose of 5000 mg, administered intraven-
ously for 2 weeks. Thereafter, the same dose was administered three times per week for
2 more weeks. Patient response was evaluated at 4 weeks. A maintenance dose of 5000
mg, administered two to three times per week, was thereafter instituted. This study re-
ported minimal side-effects and toxicity, similar to what was reported in the study with
dogs.
The current limit for HEPES in radiopharmaceutical preparations specified by the
European Pharmacopoeia. is 200 μg/V, where V represents the maximum injected dose
in millilitre. This very strict limit translates to a maximum HEPES dose of 200 μg per
dose. Labelling of specific radiopharmaceuticals may require different volumes and con-
centrations of HEPES as reported by Antunes et al. (Antunes et al. 2020).Using these
examples, in a worst-case scenario where no HEPES is removed during the labelling
process, a total single dose between 283 and 714 mg HEPES would be intravenously ad-
ministered to a patient. This translates to a HEPES dose of 4.0–10.2 mg/kg for a 70 kg
patient. The highest single dose is much lower than the maximum mg/kg dose used in
Roux et al. EJNMMI Radiopharmacy and Chemistry            (2021) 6:15 Page 2 of 4
the chronic toxicity study in dogs. This is approximately 14% of the average dose ad-
ministered to humans in the preliminary fixed dose study by Theodore et al. It is
known that a considerable amount of HEPES is removed during the purification
process. The HEPES content is therefore significantly lower than the doses used in the
Theodore toxicity study and still far below the chronic dose of 400 mg/kg where signifi-
cant changes in the hematopoietic and reticuloendothelial systems were observed.
In 2015 the FDA approved ONIVYDE™ (irinotecan, Merrimack Pharmaceuticals), a
topoisomerase 1 inhibitor which also contains HEPES as a buffering system. The
pharmaceutical formulation contains 4.05 mg/ml HEPES in a 10ml vial solution, to be
diluted in 500 ml dextrose 5% for intravenous administration (Baker and Levien 2017;
Merrimack 2015; Theodore et al. 1997a). The recommended dosage is 70 mg/m2 irino-
tecan (4.3 mg/ml) resulting in an average male (1.9 m2) receiving a total amount of 133
mg of the drug and 126mg of HEPES. This amount of administered HEPES is much
higher than the recommended 200 μg per dose for gallium-68 based radiopharmaceuti-
cals. Limiting the HEPES content to 200 μg/V as currently advised by the European
Pharmacopoeia may therefore be a far too strict limit.
The authors are aware that the studies reported are designed to evaluate the use of
HEPES as an active pharmaceutical ingredient or as an adjuvant/excipient for thera-
peutic anticancer formulations. Further toxicological studies in animals or humans may
be required to increase the European Pharmacopoeia limit for HEPES as an adjuvant
for radiopharmaceutical use.
To conclude: The expected HEPES content in radiopharmaceutical preparations is
significantly less than the doses used in the chronic toxicity study in dogs by Theodore
et al. and in the other FDA approved pharmaceutical. The HEPES content is also con-
siderably less that the dose used in humans to evaluate its effects in clinical cancer. It is
further highly unlikely that patients scheduled for Nuclear Medicine investigations will
receive a daily intravenous dose of 5000mg HEPES dose as in the Theodore study.
Taking these factors into account, regulatory institutions may consider reviewing the
current strict limit for HEPES in radiopharmaceutical preparations.
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